Table 2 Univariate analysis for time to recurrence
Characteristics | Hazard ratio (95 % CI) | p-value |
|---|---|---|
Location of primary tumor (rectum vs colon) | 0.956 (0.548–1.669) | 0.875 |
Age (≥65 vs <65) | 0.856 (0.418–1.755) | 0.671 |
Sex (female vs male) | 0.678 (0.399–1.150) | 0.150 |
Neoadjuvant chemotherapy (Yes vs No) | 1.040 (0.563–1.923) | 0.899 |
Tumor grade (moderate/poor vs well) | 1.201 (0.508–2.843) | 0.676 |
T stage (T4 vs T1-3) | 1.041 (0.608–1.782) | 0.885 |
N stage (N2 vs N0,1) | 1.197 (0.703–2.037) | 0.508 |
Resection site | ||
Liver | 1 | |
Lung | 0.694 (0.311–1.550) | 0.373 |
Others (ovary, uterus, bladder) | 0.670 (0.299–1.502) | 0.331 |
Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No) | 0.589 (0.143–2.425) | 0.463 |
Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No) | 0.582 (0.231–1.469) | 0.252 |
KRAS (mutation vs wild) | 1.245 (0.725–2.137) | 1.245 |
KRAS subtype | ||
Wild | 1 | |
12th | 1.127 (0.599–2.123) | 0.710 |
13th | 1.230 (0.561–2.697) | 0.605 |
A.A Mutation type | ||
Wild (n = 51) | 1 | |
Guanine to thymidine (n = 5) | 0.737 (0.164–3.315) | 0.691 |
Guanine to cytosine (n = 2) | 1.482 (0.766–2.864) | 0.242 |
Guanine to adenine (n = 24) | 1.029 (0.553–1.931) | 0.928 |